A Systematic Review and Meta-Analysis of Intraperitoneal Bupivacaine in Laparoscopic Gynecologic Surgery

Greg Marchand\textsuperscript{1}
Kelly Ware\textsuperscript{1,2}
Malini Govindan\textsuperscript{1}
Ahmed T Masoud\textsuperscript{1,3}
Alexa King\textsuperscript{1,2}
Stacy Ruther\textsuperscript{1}
Giovanna Brazil\textsuperscript{1}
Kaitlynne Cieminski\textsuperscript{1}
Nicolas Calteux\textsuperscript{1}
Catherine Coriell\textsuperscript{1}
Hollie Ulibarri\textsuperscript{1}
Julia Parise\textsuperscript{1}
Amanda Arroyo\textsuperscript{1}
Diana Chen\textsuperscript{4}
Maria Pierson\textsuperscript{4}
Rasa Rafie\textsuperscript{5}
Katelyn Sainz\textsuperscript{1}

\textsuperscript{1}Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA; \textsuperscript{2}International University of Health Sciences, Basseterre, St. Kitts; \textsuperscript{3}Fayoum University Faculty of Medicine, Fayoum, Egypt; \textsuperscript{4}Midwestern University College of Osteopathic Medicine, Glendale, AZ, USA; \textsuperscript{5}Rocky Vista University College of Osteopathic Medicine, Parker, CO, USA

Objective: We set out to evaluate whether the instillation of bupivacaine versus a saline solution into the peritoneal cavity at time of laparoscopic gynecologic surgery will reduce postoperative pain and postoperative opioid consumption.

Data Sources: We searched six databases: Web of Science, SCOPUS, Cochrane CENTRAL, ClinicalTrials.Gov, MEDLINE and PubMed. Our search strategy had no restriction on time or languages and included all studies that met our search algorithm up to March of 2021.

Methods of Study Selection: We included only randomized trials that met our search strategy for the outcomes of 1) pain intensity 24 hours after surgery, 2) pain intensity 6 hours after surgery, and 3) length of hospital stay.

Tabulation, Integration, and Results: We analyzed continuous data using mean difference (MD) with relative 95% confidence interval (CI). We included 8 randomized clinical trials. We found that intraperitoneal bupivacaine showed significant difference from the saline group regarding pain intensity 24 hours after surgery (MD= −0.73 [−1.10, −0.36]) (P = 0.01) and pain intensity 6 hours after surgery (MD= −1.12 [−2.22, −0.02]) (P = 0.05). Overall, patients allocated to the placebo group seemed to need other analgesics earlier than patients allocated to the bupivacaine group (MD=145.08 [51.37, 238.79] (P = 0.02)). There was no significant difference regarding the length of hospital stay (MD= −0.44 [−1.44, 0.56]) (P = 0.39).

Conclusion: Bupivacaine significantly reduced the visual analog pain score for pain compared with that of the placebo at 6 and 24 hours postoperatively. There was no significant difference in hospital stay.

Prospero Registration: CRD42021254268.

Keywords: ERAS, marcaine, bupivacaine, enhanced recovery after surgery, intra-abdominal anesthetic

Introduction

Gynecologic surgery is very prevalent in the United States, comprising 26.5% of all surgeries performed on women.\textsuperscript{1} Postoperative pain is one of the most important complications of gynecologic surgeries. Approximately 86% of patients suffer from postoperative pain, and about 75% of those report that the pain is moderate to severe.\textsuperscript{2} Improvements in postoperative pain management could lead to shorter hospital stays, decreased costs, earlier mobilization and prevention of thrombosis, and decreased morbidity.\textsuperscript{3,4} Chronic postoperative pain increases sympathetic tone, which in turn may increase molecular catabolism, resulting in abnormal muscle functioning.\textsuperscript{5} Substantial pain after laparoscopic gynecologic surgeries may require...
large doses of opioids in the first 24 hours after the procedure, which can lead to the additional complications of opioid tolerance and habituation. Several authors have suggested that the administration of local analgesics may reduce the total need for opioids in the first 24 hours postoperatively. Preemptive anesthesia has been attempted in many forms, including local injection at the surgery site, epidural, or in a systematic manner just before surgical incision. Local anesthetics can also be injected at incisional sites and placed intraperitoneal in an attempt to decrease both visceral and somatic pain.

Despite the fact that many different local anesthetics have been attempted in the preoperative, intraoperative, and postoperative periods, there remains no clear consensus as to the best local anesthetic or the best route of administration. Some authors have suggested simply pouring local anesthetics into the abdominal cavity, as the majority of the patient’s pain in the postoperative period does seem deep in the abdomen following laparoscopy. Some authors have discussed that this method may decrease patient safety as abdominal anesthetics likely have higher intravascular absorption than other methods of administration. Cases of toxicity have been reported, a specific syndrome of local anesthetic systemic toxicity (LAST) has been described.

Bupivacaine is a long acting, potent local anesthetic agent that is commonly used in gynecologic surgery. In this meta-analysis, we evaluate whether the intraperitoneal placement of a bupivacaine solution versus a saline solution reduces postoperative pain in women undergoing laparoscopic gynecologic surgery, and whether there is a decrease in hospital stay, or time until first required opioid administration.

Methods
Strict adherence was undertaken in every step of our meta-analysis and systematic review. As guidelines for this undertaking we used the checklist for “Preferred Reporting Items for Systematic Reviews and Meta-analyses” (PRISMA), and followed all steps to the letter. Every step of this systematic review was also performed in complete concordance with the instructions included in Cochrane’s “handbook of systematic reviews of interventions”.

Literature Search
We searched Web of Science, SCOPUS, Cochrane CENTRAL, ClinicalTrials.Gov, MEDLINE and PubMed, for published trials without any restrictions on time or languages. We used the following search strategy: (mar-caine OR Bupivacaine OR Sensorcaine OR Posimir) AND (“gynecologic surgery”).

Inclusion Criteria
The following five criteria were utilized to define eligibility: (I) Patient Population: all female patients undergoing a laparoscopic gynecologic surgery. (ii) Intervention: Bupivacaine (iii) comparator: Placebo. (IV) Outcomes: Pain intensity 24 hours after surgery, Pain intensity 6 hours after surgery, elapsed time for the first non-local analgesic dose, and length of hospital stay. (v) Study design: Only randomized controlled trials were included in our study (RCTs). We excluded any clinical trials that were non-randomized, trials that did not measure for our selected outcomes, studies whose participants were healthy volunteers without surgical intervention, studies without a control group, and animal studies.

Screening of Results
We scanned the reference list of retrieved studies using Endnote software. Following the automatic deletion of all duplicate studies, we looked at the remaining studies using a two step process. This included first looking at the abstract, and then only moving on to a full text screening on those articles that were found in the first step to meet our criteria.

Data Extraction and Analysis
Two independent authors extracted the data from the included studies. We extracted the data of all of the major categories required in this work. This included 3 basic categories of data as follows:

1) Demographic data of the patients in each of the included studies. This included body mass index (BMI), patient age, surgery performed, and the duration of the surgery in minutes.

2) Outcome data for our meta-analysis: Pain intensity 24 hours after surgery, pain intensity 6 hours after surgery, elapsed time until the first analgesic dose, and length of hospital stay.

3) Data about the risk of bias from each study, in order to complete Cochrane’s risk of bias analysis of our review.

Analysis of Data
RevMan (version 5.4.1) was utilized in order to perform the meta-analysis. The inverse variance method was used. Data for continuous outcomes were extracted and pooled using the techniques of mean difference (MD) and standard deviation,
relative to a ninety-five percent confidence interval (CI), while data for those outcomes which were dichotomous were extracted and reported using percent and total. We assessed heterogeneity among studies by visual inspection of the forest plots, the I-square test (I²), and the P-value of the Chi-square test. The overall analysis of outcomes in the cases where \( I^2 > 50\% \), \( P<0.1 \) were considered heterogeneous, and those values where \( I^2 < 50\% \), \( P=0.1 \) were considered homogeneous, as is suggested in adhering to the “The Cochrane Handbook”.

We performed an analysis of the homogeneous outcomes under a fixed-effects model using the Mantel Haenszel (M-H) method, while those outcomes that were heterogeneous were analyzed using the “random-effects” model.

Quality Assessment
To assess the risk of bias of the included randomized clinical trials, we conducted the quality assessment of this study according to the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). We used Cochrane’s risk of bias assessment tool which includes the following domains: sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selection outcome reporting (reporting bias), and other potential sources of bias.

Results
Summary of Included Clinical Trials
The electronic search results are described in detail in Figure 1, which shows a PRISMA diagram of our search and screening process. We performed the analysis of 532 patients undergoing different laparoscopic gynecological surgeries from eight studies, with a total of 265 patients allocated to the bupivacaine group, and 267 patients allocated to the placebo group. The average age of participants in the bupivacaine group was 37.08 years and the average age of the placebo group was 37.58 years. Table 1 shows a complete summary of the included patients, including their demographic data, body mass index (BMI), and the duration of surgery.

Results of Risk of Bias Assessment
The overall quality assessment was a low risk of bias according to Cochrane’s tool. All studies were at low risk of bias regarding randomization, blinding of participants and personnel, attrition, and selective reporting bias. Concerning allocation concealment, 5 studies reported proper allocation concealment, and therefore they were judged to be at low risk of bias. Three studies did not report enough data about concealment so they were categorized as an unclear risk of bias. Concerning blinding of outcome assessment, three studies revealed adequate blinding of the outcome assessors so they were categorized as low risk of bias, while the remaining studies were categorized as an unclear risk of bias. Supplemental File 1 shows an illustration of the individual risks of bias of the included studies.

Analysis of Outcomes
Pain Intensity 24 Hours After Surgery
Six studies reported VAS pain scores after 24 hours. The overall estimate favored the bupivacaine group significantly (MD= −0.73 [−1.10, −0.36], \( P = 0.01 \)). We found significant heterogeneity (\( P = 0.01 \); \( I^2 = 66\% \)) (Figure 2A). In order to solve heterogeneity, we excluded Badawy 2017 (\( P = 0.12 \); \( I^2 = 45\% \)). Pooled analysis after solving heterogeneity also favored the bupivacaine group significantly (MD= −0.66 [−0.93, −0.39], \( P = 0.01 \)) (Figure 2B).

Pain Intensity 6 Hours After Surgery
Five studies reported VAS pain scores after six hours. Pooled analysis showed that bupivacaine was superior to placebo in reducing pain after six hours (MD= −1.12 [−2.22, −0.02], \( P = 0.05 \)). Data was heterogeneous (\( P = 0.03 \); \( I^2 = 81\% \)) as shown in Figure 3A. We solved the heterogeneity by excluding Arden et al. (\( P = 0.59 \); \( I^2 = 0\% \)). The combined analysis after solving heterogeneity also favored the bupivacaine group significantly (MD= −1.85 [−2.15, −1.55]) as shown in Figure 3B.

Length of Hospital Stay (Hours)
Two studies reported the length of hospital stay. The overall estimate showed no significant difference between either group (MD= −0.44 [−1.44, 0.56], \( P = 0.39 \)). No significant heterogeneity was found between studies (\( P = 0.27 \); \( I^2 = 16\% \)) as shown in Figure 4.

Elapsed Time Prior to the First Non-Local Analgesic Dose (in Minutes)
Three studies estimated the elapsed time prior to the first non-local analgesic dose and the analysis showed that patients allocated to placebo group needed analgesics earlier than patients allocated to bupivacaine group (MD=145.08 [51.37, 238.79], \( P = 0.02 \)). Pooled analysis was heterogeneous (\( P < 0.01 \); \( I^2 = 97\% \)) as seen in...
Figure 5A. We solved heterogeneity by leaving out Karsli et al 2003\(^25\) (\(P = 0.50\)); \(I^2 = 0\%). The analysis after solving heterogeneity also favored bupivacaine the group significantly (MD=192.54 [167.25, 217.84], (\(P < 0.01\)) as shown in Figure 5B.

**Discussion**

In this systematic review, we included 8 randomized clinical trials that evaluated the effect of intra-abdominal local analgesic on postoperative pain after various laparoscopic gynecological surgeries. Our meta-analysis showed a significant reduction in VAS score for pain in the bupivacaine group compared with that of the placebo at 6 and 24 hours postoperatively.

A previous meta-analysis performed by Marks et al\(^31\) suggested that intraperitoneal local analgesia was very effective in the reduction of postoperative pain at 2 and 6 hours after Laparoscopic Gynecologic surgery, and that bupivacaine did not seem to have any major side effects. These results were consistent with our findings. The major
limitation of this previous meta-analysis was the relatively small number of patients. Therefore, analyzing the data nine years later, we were able to include far more trials in the present meta-analysis to provide large-scale evidence of the effect of intraperitoneal bupivacaine on postoperative pain.

Multiple trials have shown a benefit to the subcutaneous injection of bupivacaine into tissues around the wound in a technique similar to using lidocaine for local short-acting anesthesia.26,32–34 These studies have ranged from small cohort studies to large RCT’s and looked at fractionated and unfractionated forms, as well as preoperative and postoperative administration.33–36 Therefore, it would make sense that intraperitoneal bupivacaine could also be beneficial.

Lastly, a major impetus of this study was the sediment from our authors that postoperative pain from gynecologic surgeries, especially laparoscopic and vaginal hysterectomy, from the perspective of any experienced surgery is intra-abdominal pain. Examination of these patients soon after surgery shows tender abdomens that do not tolerate deep examination, it does not show point tenderness to superficial wounds, as one might commonly see, for example, with a herpes or shingles lesion. Therefore the superiority of intraperitoneal bupivacaine to subcutaneous or local injection, to our authors, seems obvious.

Table 1 Detailed Summary of the Included Participants, Their Demographic Data, and Types of Operations

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample Size</th>
<th>Age, Years (Mean ± SD)</th>
<th>BMI (Kg/m²)</th>
<th>Operation Time (mins)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bupivacaine</td>
<td>Control</td>
<td>Bupivacaine</td>
<td>Placebo</td>
</tr>
<tr>
<td>Arden 2013</td>
<td>80</td>
<td>44.1±6.4</td>
<td>44.9±7.1</td>
<td>28.4±7.6</td>
</tr>
<tr>
<td>Badawy 2017</td>
<td>10</td>
<td>46.40±3.21</td>
<td>46.20±4.32</td>
<td>31.60±1.14</td>
</tr>
<tr>
<td>Butala 2013</td>
<td>30</td>
<td>34.3±9.26</td>
<td>33.7±7.69</td>
<td>NR</td>
</tr>
<tr>
<td>Chou 2005</td>
<td>30</td>
<td>31.6±7.9</td>
<td>35.1±11.0</td>
<td>22.8±3.5</td>
</tr>
<tr>
<td>Karsli 2003</td>
<td>20</td>
<td>38.7±7.8</td>
<td>39.8±8.3</td>
<td>NR</td>
</tr>
<tr>
<td>Kayacan 2002</td>
<td>20</td>
<td>38.7±7.8</td>
<td>38.7±7.8</td>
<td>NR</td>
</tr>
<tr>
<td>Keita 2003</td>
<td>15</td>
<td>31.8±5.6</td>
<td>32.5±5.2</td>
<td>NR</td>
</tr>
<tr>
<td>Shalan 2002</td>
<td>60</td>
<td>31.1±4.2</td>
<td>29.8±3.7</td>
<td>NR</td>
</tr>
</tbody>
</table>

Note: Data are reported as mean ± SD.
Abbreviations: NR, not reported; BMI, body-mass index.

Figure 2 (A and B) show forest plots of patient pain at 24 hours after surgery, before (A) and after (B) removing Badawy et al 2017 to solve heterogeneity.
Figure 3 (A and B) show forest plots of patient pain at 6 hours after surgery, before (A) and after (B) removing Arden et al 2013 to solve heterogeneity.

Figure 4 Shows the forest plot of the outcomes for length of hospital stay.

Figure 5 (A and B) show forest plots of the elapsed time prior to the first non-local analgesic dose, before (A) and after (B) removing Karsli et al 2003 to solve heterogeneity.
Strengths
The major strength of our study was our inclusion of only those clinical trials which were properly randomized and controlled for. According to the GRADE guideline, this should provide the highest level of evidence. Another strength of our study was the risk of bias, as all of the included studies were judged to be at a low risk of bias, almost universally in all categories. Next, our patient sample size in the included studies was quite large, including 534 total patients. This speaks to higher quality evidence. Lastly, we were able to solve the heterogeneity that was found in our results using only appropriate, recognized techniques that can be found within Cochrane’s handbook.22

Limitations
Although the biggest single limitation facing this study was the heterogeneity in some of our outcomes, we were able to track down the individual attributing factors and solve the heterogeneity in all cases. Another limitation includes the inherent weaknesses of subjective pain scales such as the VAS,37 although our authors do not have a better system to propose at this time. Lastly, although our goal was to find the existence of an effect, the fact that the doses used were not standardized is another weakness of our study.

Conclusion
We conclude that intraperitoneal bupivacaine significantly reduced the VAS score for pain compared with that of the placebo at 6 and 24 hours. This efficacy may lead surgeons to consider intraperitoneal administration in laparoscopic gynecologic surgical procedure. Further studies are needed to determine the best local anesthetic and route of administration for minimization of postoperative pain in laparoscopic gynecologic surgery.

Data Sharing Statement
All supporting data is included or referenced in this manuscript. The authors have no additional data used in this study.

Ethics Approval and Consent to Participate
This Manuscript has been reviewed by the institutional IRB board at Marchand Institute and was found to be exempt from IRB review (March 2021). Data used was exempt from consent to participate or publish secondary to the nature of the study being a systematic review, retrospectively looking at previously published data.

Consent to Publish
Data used was exempt from consent to participate or publish secondary to the nature of the study being a systematic review, retrospectively looking at previously published data.

Patient Consent
Not applicable to systematic review.

Acknowledgments
The Marchand Institute for Minimally Invasive Surgery would like to acknowledge the efforts of all of the students, researchers, residents and fellows at the institute who put their time and effort into these projects without compensation, only for the betterment of women’s health. We firmly assure them that the future of medicine belongs to them.

Author Contributions
All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding
No funding was received for this study.

Disclosure
The authors declare no competing interests.

References


